{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:57:57Z","timestamp":1792699077692,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/nrdp.2017.44","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T12:18:05Z","timestamp":1499861885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":264,"title":["Tumour-induced osteomalacia"],"prefix":"10.1038","volume":"3","author":[{"given":"Salvatore","family":"Minisola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munro","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seijii","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Tella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"BFnrdp201744_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe, A. L. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28, 1\u201330 (2004). An extensive evaluation of the histological aspects of osteomalacia associated with mesenchymal tumours.","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrdp201744_CR2","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong, W. H., Molinolo, A. A., Chen, C. C. & Collins, M. T. Tumor-induced osteomalacia. Endocr. Relat. Cancer 18, R53\u2013R77 (2011). An in-depth review covering various aspects of TIO.","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrdp201744_CR3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bone.2004.08.009","volume":"35","author":"B Bielesz","year":"2004","unstructured":"Bielesz, B., Klaushofer, K. & Oberbauer, R. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 35, 1229\u20131239 (2004).","journal-title":"Bone"},{"key":"BFnrdp201744_CR4","unstructured":"Carpenter, T. O. Primary disorders of phosphate metabolism. EndoTexthttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279172\/ (2014). A general review of phosphate metabolism and related disorders."},{"key":"BFnrdp201744_CR5","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/MPH.0000000000000686","volume":"39","author":"SS Crossen","year":"2017","unstructured":"Crossen, S. S. et al. Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J. Pediatr. Hematol. Oncol. 39, e21\u2013e24 (2017).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"BFnrdp201744_CR6","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","volume":"91","author":"EA Imel","year":"2006","unstructured":"Imel, E. A. et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 91, 2055\u20132061 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang, Y. et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J. Bone Miner. Res. 27, 1967\u20131975 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo, I. et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr. J. 62, 811\u2013816 (2015).","journal-title":"Endocr. J."},{"key":"BFnrdp201744_CR9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(72)92844-9","volume":"1","author":"DJ Evans","year":"1972","unstructured":"Evans, D. J. & Azzopardi, J. G. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet 1, 353\u2013354 (1972).","journal-title":"Lancet"},{"key":"BFnrdp201744_CR10","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","volume":"59","author":"N Weidner","year":"1987","unstructured":"Weidner, N. & Santa Cruz, D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59, 1442\u20131454 (1987).","journal-title":"Cancer"},{"key":"BFnrdp201744_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1210\/jc.2013-3791","volume":"99","author":"J Sahoo","year":"2014","unstructured":"Sahoo, J. et al. Tumor(s) induced osteomalacia \u2014 a curious case of double trouble. J. Clin. Endocrinol. Metab. 99, 395\u2013398 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00256-015-2246-x","volume":"44","author":"M Higley","year":"2015","unstructured":"Higley, M., Beckett, B., Schmahmann, S., Dacey, E. & Foss, E. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia. Skeletal Radiol. 44, 1825\u20131831 (2015).","journal-title":"Skeletal Radiol."},{"key":"BFnrdp201744_CR13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/jc.2015-3854","volume":"101","author":"AK Annamalai","year":"2016","unstructured":"Annamalai, A. K. et al. Needle(s) in the haystack \u2014 synchronous multifocal tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 390\u2013393 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1210\/jc.2012-3473","volume":"98","author":"DE Leaf","year":"2013","unstructured":"Leaf, D. E., Pereira, R. C., Bazari, H. & Juppner, H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J. Clin. Endocrinol. Metab. 98, 887\u2013891 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-93-2-275","volume":"93","author":"KW Lyles","year":"1980","unstructured":"Lyles, K. W., Berry, W. R., Haussler, M., Harrelson, J. M. & Drezner, M. K. Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann. Intern. Med. 93, 275\u2013278 (1980).","journal-title":"Ann. Intern. Med."},{"key":"BFnrdp201744_CR16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00520-012-1474-z","volume":"20","author":"MP Mak","year":"2012","unstructured":"Mak, M. P. et al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support. Care Cancer 20, 2195\u20132197 (2012).","journal-title":"Support. Care Cancer"},{"key":"BFnrdp201744_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/ddt429","volume":"23","author":"YH Lim","year":"2014","unstructured":"Lim, Y. H. et al. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum. Mol. Genet. 23, 397\u2013407 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrdp201744_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jc.2013-4290","volume":"99","author":"D Ovejero","year":"2014","unstructured":"Ovejero, D. & Collins, M. T. RAS in FGF23: another piece in the puzzle. J. Clin. Endocrinol. Metab. 99, 63\u201366 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","volume":"75","author":"YH Lim","year":"2016","unstructured":"Lim, Y. H. et al. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J. Am. Acad. Dermatol. 75, 420\u2013427 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrdp201744_CR20","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s00198-016-3702-8","volume":"27","author":"D Ovejero","year":"2016","unstructured":"Ovejero, D. et al. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos. Int. 27, 3615\u20133626 (2016). An in-depth review of the cutaneous skeletal hypophosphataemia syndrome.","journal-title":"Osteoporos. Int."},{"key":"BFnrdp201744_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0000000000000290","volume":"39","author":"JM Carter","year":"2015","unstructured":"Carter, J. M., Caron, B. L., Dogan, A. & Folpe, A. L. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am. J. Surg. Pathol. 39, 75\u201383 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrdp201744_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bone.2003.10.005","volume":"34","author":"PS Rowe","year":"2004","unstructured":"Rowe, P. S. et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34, 303\u2013319 (2004).","journal-title":"Bone"},{"key":"BFnrdp201744_CR23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/jc.2004-0357","volume":"90","author":"TO Carpenter","year":"2005","unstructured":"Carpenter, T. O. et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90, 1012\u20131020 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI18563","volume":"112","author":"T Berndt","year":"2003","unstructured":"Berndt, T. et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112, 785\u2013794 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201744_CR25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","volume":"17","author":"SM De Beur","year":"2002","unstructured":"De Beur, S. M. et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res. 17, 1102\u20131110 (2002).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4158\/EP.14.9.1108","volume":"14","author":"MA Habra","year":"2008","unstructured":"Habra, M. A. et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr. Pract. 14, 1108\u20131114 (2008).","journal-title":"Endocr. Pract."},{"key":"BFnrdp201744_CR27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00774-011-0290-8","volume":"30","author":"Y Imanishi","year":"2012","unstructured":"Imanishi, Y. et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J. Bone Miner. Metab. 30, 93\u201399 (2012).","journal-title":"J. Bone Miner. Metab."},{"key":"BFnrdp201744_CR28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci, M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112, 683\u2013692 (2003). A seminal paper showing that FGF23 is produced by fibrous dysplasia tissue.","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201744_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","volume":"23","author":"D Sitara","year":"2004","unstructured":"Sitara, D. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23, 421\u2013432 (2004).","journal-title":"Matrix Biol."},{"key":"BFnrdp201744_CR30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","volume":"35","author":"M Mirams","year":"2004","unstructured":"Mirams, M., Robinson, B. G., Mason, R. S. & Nelson, A. E. Bone as a source of FGF23: regulation by phosphate? Bone 35, 1192\u20131199 (2004).","journal-title":"Bone"},{"key":"BFnrdp201744_CR31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.4465","volume":"235","author":"JC Lee","year":"2015","unstructured":"Lee, J. C. et al. Identification of a novel FN1\u2013FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J. Pathol. 235, 539\u2013545 (2015).","journal-title":"J. Pathol."},{"key":"BFnrdp201744_CR32","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","volume":"29","author":"JC Lee","year":"2016","unstructured":"Lee, J. C. et al. Characterization of FN1\u2013FGFR1 and novel FN1\u2013FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod. Pathol. 29, 1335\u20131346 (2016). A paper that demonstrates the central role of the FGF1\u2013FGFR1 signalling pathway.","journal-title":"Mod. Pathol."},{"key":"BFnrdp201744_CR33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semcdb.2015.10.012","volume":"53","author":"Y Tanner","year":"2016","unstructured":"Tanner, Y. & Grose, R. P. Dysregulated FGF signalling in neoplastic disorders. Semin. Cell Dev. Biol. 53, 126\u2013135 (2016).","journal-title":"Semin. Cell Dev. Biol."},{"key":"BFnrdp201744_CR34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejmech.2016.11.052","volume":"126","author":"W Cheng","year":"2017","unstructured":"Cheng, W., Wang, M., Tian, X. & Zhang, X. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. Eur. J. Med. Chem. 126, 476\u2013490 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"BFnrdp201744_CR35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","volume":"28","author":"S Wohrle","year":"2013","unstructured":"Wohrle, S. et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J. Bone Miner. Res. 28, 899\u2013911 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1358\/dof.2010.035.09.1526651","volume":"35","author":"EA Imel","year":"2010","unstructured":"Imel, E. A. & Peacock, M. X-linked hypophosphatemia: understanding and management. Drugs Future 35, 755\u2013763 (2010).","journal-title":"Drugs Future"},{"key":"BFnrdp201744_CR37","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1113\/jphysiol.2014.273979","volume":"592","author":"E Lederer","year":"2014","unstructured":"Lederer, E. Regulation of serum phosphate. J. Physiol. 592, 3985\u20133995 (2014).","journal-title":"J. Physiol."},{"key":"BFnrdp201744_CR38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mce.2008.08.031","volume":"310","author":"S Fukumoto","year":"2009","unstructured":"Fukumoto, S. The role of bone in phosphate metabolism. Mol. Cell. Endocrinol. 310, 63\u201370 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"BFnrdp201744_CR39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429\u2013435 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/ki.1996.264","volume":"49","author":"H Murer","year":"1996","unstructured":"Murer, H. et al. Renal brush border membrane Na\/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int. 49, 1769\u20131773 (1996).","journal-title":"Kidney Int."},{"key":"BFnrdp201744_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","volume":"16","author":"JE Blau","year":"2015","unstructured":"Blau, J. E. & Collins, M. T. The PTH\u2013vitamin D\u2013FGF23 axis. Rev. Endocr. Metab. Disord. 16, 165\u2013174 (2015).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"BFnrdp201744_CR42","doi-asserted-by":"crossref","first-page":"231s","DOI":"10.1111\/j.1365-2265.1977.tb03387.x","volume":"7","author":"M Peacock","year":"1977","unstructured":"Peacock, M., Heyburn, P. J. & Aaron, J. E. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1\u03b1-hydroxyvitamin D3 . Clin. Endocrinol. (Oxf.) 7, 231s\u2013237s (1977).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrdp201744_CR43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000346786","volume":"180","author":"S Kido","year":"2013","unstructured":"Kido, S., Kaneko, I., Tatsumi, S., Segawa, H. & Miyamoto, K. Vitamin D and type II sodium-dependent phosphate cotransporters. Contrib. Nephrol. 180, 86\u201397 (2013).","journal-title":"Contrib. Nephrol."},{"key":"BFnrdp201744_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/978-1-4684-5101-6_24","volume":"196","author":"HF DeLuca","year":"1986","unstructured":"DeLuca, H. F. The metabolism and functions of vitamin D. Adv. Exp. Med. Biol. 196, 361\u2013375 (1986).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnrdp201744_CR45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5414\/CN107322","volume":"79","author":"Y Sabbagh","year":"2013","unstructured":"Sabbagh, Y. Phosphate as a sensor and signaling molecule. Clin. Nephrol. 79, 57\u201365 (2013).","journal-title":"Clin. Nephrol."},{"key":"BFnrdp201744_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.ackd.2011.01.004","volume":"18","author":"C Bergwitz","year":"2011","unstructured":"Bergwitz, C. & Juppner, H. Phosphate sensing. Adv. Chronic Kidney Dis. 18, 132\u2013144 (2011).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"BFnrdp201744_CR47","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov, I. Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003\u20134008 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201744_CR48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbrc.2005.01.033","volume":"328","author":"T Jaaskelainen","year":"2005","unstructured":"Jaaskelainen, T., Huhtakangas, J. & Maenpaa, P. H. Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y. Biochem. Biophys. Res. Commun. 328, 831\u2013837 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrdp201744_CR49","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","volume":"49","author":"Y Rhee","year":"2011","unstructured":"Rhee, Y. et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636\u2013643 (2011).","journal-title":"Bone"},{"key":"BFnrdp201744_CR50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","volume":"22","author":"JL Geller","year":"2007","unstructured":"Geller, J. L. et al. Cinacalcet in the management of tumor-induced osteomalacia. J. Bone Miner. Res. 22, 931\u2013937 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR51","unstructured":"Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride (National Academies Press, 1997)."},{"key":"BFnrdp201744_CR52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0002-8223(98)00160-6","volume":"98","author":"AA Yates","year":"1998","unstructured":"Yates, A. A., Schlicker, S. A. & Suitor, C. W. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J. Am. Diet Assoc. 98, 699\u2013706 (1998).","journal-title":"J. Am. Diet Assoc."},{"key":"BFnrdp201744_CR53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1201\/b16906-3","volume-title":"The Physiological Basis of Metabolic Bone Disease","author":"JC Fleet","year":"2014","unstructured":"Fleet, J. C. & Peacock, M. in The Physiological Basis of Metabolic Bone Disease (eds Morris, H. A., Anderson, P. H. & Christopher Nordin, B. E. ) 13\u201340 (CRC Press, 2014)."},{"key":"BFnrdp201744_CR54","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","volume":"20","author":"Y Sabbagh","year":"2009","unstructured":"Sabbagh, Y. et al. Intestinal Npt2b plays a major role in phosphate absorption and homeostasis. J. Am. Soc. Nephrol. 20, 2348\u20132358 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrdp201744_CR55","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett, S. M. et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21, 1187\u20131196 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR56","doi-asserted-by":"crossref","first-page":"11085","DOI":"10.1073\/pnas.0704446104","volume":"104","author":"T Berndt","year":"2007","unstructured":"Berndt, T. et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc. Natl Acad. Sci. USA 104, 11085\u201311090 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201744_CR57","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1681\/ASN.2014030317","volume":"26","author":"ED Labonte","year":"2015","unstructured":"Labonte, E. D. et al. Gastrointestinal inhibition of sodium\u2013hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J. Am. Soc. Nephrol. 26, 1138\u20131149 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrdp201744_CR58","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1681\/ASN.2016080855","volume":"28","author":"GA Block","year":"2017","unstructured":"Block, G. A. et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J. Am. Soc. Nephrol. 28, 1933\u20131942 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrdp201744_CR59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1113\/expphysiol.2005.032516","volume":"91","author":"J Marks","year":"2006","unstructured":"Marks, J. et al. Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice. Exp. Physiol. 91, 531\u2013537 (2006).","journal-title":"Exp. Physiol."},{"key":"BFnrdp201744_CR60","doi-asserted-by":"crossref","first-page":"C429","DOI":"10.1152\/ajpcell.00331.2004","volume":"288","author":"P Capuano","year":"2005","unstructured":"Capuano, P. et al. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1\u03b1OHase-deficient mice. Am. J. Physiol. Cell Physiol. 288, C429\u2013C434 (2005).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"BFnrdp201744_CR61","doi-asserted-by":"crossref","first-page":"73s","DOI":"10.1111\/j.1365-2265.1977.tb03365.x","volume":"7","author":"M Peacock","year":"1977","unstructured":"Peacock, M., Aaron, J. E., Walker, G. S. & Davison, A. M. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1\u03b1-hydroxyvitamin D3 . Clin. Endocrinol. (Oxf.) 7, 73s\u201381s (1977).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrdp201744_CR62","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(83)90443-2","volume":"85","author":"GR Davis","year":"1983","unstructured":"Davis, G. R. et al. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology 85, 908\u2013916 (1983).","journal-title":"Gastroenterology"},{"key":"BFnrdp201744_CR63","doi-asserted-by":"crossref","first-page":"C1262","DOI":"10.1152\/ajpcell.00456.2002","volume":"284","author":"H Xu","year":"2003","unstructured":"Xu, H., Inouye, M., Hines, E. R., Collins, J. F. & Ghishan, F. K. Transcriptional regulation of the human NaPi-IIb cotransporter by EGF in Caco-2 cells involves c-myb. Am. J. Physiol. Cell Physiol. 284, C1262\u2013C1271 (2003).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"BFnrdp201744_CR64","doi-asserted-by":"crossref","first-page":"E903","DOI":"10.1152\/ajpendo.00620.2011","volume":"302","author":"P Khuituan","year":"2012","unstructured":"Khuituan, P. et al. Fibroblast growth factor-23 abolishes 1,25-dihydroxyvitamin D3-enhanced duodenal calcium transport in male mice. Am. J. Physiol. Endocrinol. Metab. 302, E903\u2013E913 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrdp201744_CR65","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/508263","volume":"79","author":"A Corut","year":"2006","unstructured":"Corut, A. et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am. J. Hum. Genet. 79, 650\u2013656 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrdp201744_CR66","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ccr3.532","volume":"4","author":"L Stokman","year":"2016","unstructured":"Stokman, L. et al. A case of pulmonary alveolar microlithiasis associated with a homozygous 195 kb deletion encompassing the entire SLC34A2 gene. Clin. Case Rep. 4, 412\u2013415 (2016).","journal-title":"Clin. Case Rep."},{"key":"BFnrdp201744_CR67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","volume":"27","author":"D Tiosano","year":"2009","unstructured":"Tiosano, D. & Hochberg, Z. Hypophosphatemia: the common denominator of all rickets. J. Bone Miner. Metab. 27, 392\u2013401 (2009).","journal-title":"J. Bone Miner. Metab."},{"key":"BFnrdp201744_CR68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2015-2175","volume":"101","author":"CF Munns","year":"2016","unstructured":"Munns, C. F. et al. Global consensus recommendations on prevention and management of nutritional rickets. J. Clin. Endocrinol. Metab. 101, 394\u2013415 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR69","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bone.2009.01.005","volume":"45","author":"JJ Kazama","year":"2009","unstructured":"Kazama, J. J. Oral phosphate binders: history and prospects. Bone 45 (Suppl. 1), S8\u2013S12 (2009).","journal-title":"Bone"},{"key":"BFnrdp201744_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/000992289503400202","volume":"34","author":"EK Pivnick","year":"1995","unstructured":"Pivnick, E. K., Kerr, N. C., Kaufman, R. A., Jones, D. P. & Chesney, R. W. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin. Pediatr. (Phila.) 34, 73\u201378 (1995).","journal-title":"Clin. Pediatr. (Phila.)"},{"key":"BFnrdp201744_CR71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/B978-0-12-397166-1.00031-X","volume-title":"The Parathyroids","author":"M Peacock","year":"2015","unstructured":"Peacock, M. in The Parathyroids 3rd edn (eds Bilezikian, J. P. et al.) 455\u2013467 (2015). An extensive review on the role of the kidney in regulating mineral metabolism."},{"key":"BFnrdp201744_CR72","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/jps.22614","volume":"100","author":"K Miyamoto","year":"2011","unstructured":"Miyamoto, K. et al. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J. Pharm. Sci. 100, 3719\u20133730 (2011).","journal-title":"J. Pharm. Sci."},{"key":"BFnrdp201744_CR73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","volume":"2","author":"RJ Walton","year":"1975","unstructured":"Walton, R. J. & Bijvoet, O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet 2, 309\u2013310 (1975).","journal-title":"Lancet"},{"key":"BFnrdp201744_CR74","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500\u20136505 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201744_CR75","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0802836","volume":"359","author":"Z Karim","year":"2008","unstructured":"Karim, Z. et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N. Engl. J. Med. 359, 1128\u20131135 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201744_CR76","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2016070726","volume":"28","author":"C Ansermet","year":"2017","unstructured":"Ansermet, C. et al. Renal Fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytropic retroviral receptor in the nephron. J. Am. Soc. Nephrol. 28, 1073\u20131078 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrdp201744_CR77","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1359\/jbmr.080220","volume":"23","author":"H Wang","year":"2008","unstructured":"Wang, H. et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J. Bone Miner. Res. 23, 939\u2013948 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR78","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00726-011-0877-3","volume":"40","author":"T Wallimann","year":"2011","unstructured":"Wallimann, T., Tokarska-Schlattner, M. & Schlattner, U. The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40, 1271\u20131296 (2011).","journal-title":"Amino Acids"},{"key":"BFnrdp201744_CR79","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/1097-4598(200009)23:9<1316::AID-MUS2>3.0.CO;2-I","volume":"23","author":"Z Argov","year":"2000","unstructured":"Argov, Z., Lofberg, M. & Arnold, D. L. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 23, 1316\u20131334 (2000).","journal-title":"Muscle Nerve"},{"key":"BFnrdp201744_CR80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/nbm.1192","volume":"20","author":"GJ Kemp","year":"2007","unstructured":"Kemp, G. J., Meyerspeer, M. & Moser, E. Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: a quantitative review. NMR Biomed. 20, 555\u2013565 (2007).","journal-title":"NMR Biomed."},{"key":"BFnrdp201744_CR81","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1096\/fj.201600473R","volume":"30","author":"DH Pesta","year":"2016","unstructured":"Pesta, D. H. et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB J. 30, 3378\u20133387 (2016).","journal-title":"FASEB J."},{"key":"BFnrdp201744_CR82","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2044.1977.tb10002.x","volume":"32","author":"R MacDonald","year":"1977","unstructured":"MacDonald, R. Red cell 2,3-diphosphoglycerate and oxygen affinity. Anaesthesia 32, 544\u2013553 (1977).","journal-title":"Anaesthesia"},{"key":"BFnrdp201744_CR83","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.1996.135","volume":"49","author":"MP Kavanaugh","year":"1996","unstructured":"Kavanaugh, M. P. & Kabat, D. Identification and characterization of a widely expressed phosphate transporter\/retrovirus receptor family. Kidney Int. 49, 959\u2013963 (1996).","journal-title":"Kidney Int."},{"key":"BFnrdp201744_CR84","first-page":"33","volume":"16","author":"RA McCance","year":"1947","unstructured":"McCance, R. A. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q. J. Med. 16, 33\u201346 (1947).","journal-title":"Q. J. Med."},{"key":"BFnrdp201744_CR85","first-page":"83","volume-title":"Metabolic Bone and Stone Disease","author":"M Peacock","year":"1993","unstructured":"Peacock, M. in Metabolic Bone and Stone Disease 3rd edn (eds Nordin, B. E. C., Need, A. G. & Morris, H. A. ) 83\u2013118 (Churchill Livingstone, 1993)."},{"key":"BFnrdp201744_CR86","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/en.2010-1109","volume":"152","author":"Y Wang","year":"2011","unstructured":"Wang, Y. & DeLuca, H. F. Is the vitamin D receptor found in muscle? Endocrinology 152, 354\u2013363 (2011).","journal-title":"Endocrinology"},{"key":"BFnrdp201744_CR87","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-13-0581","volume":"170","author":"S Piemonte","year":"2014","unstructured":"Piemonte, S. et al. Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur. J. Endocrinol. 170, K1\u2013K4 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrdp201744_CR88","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan de Beur","year":"2005","unstructured":"Jan de Beur, S. M. Tumor-induced osteomalacia. JAMA 294, 1260\u20131267 (2005).","journal-title":"JAMA"},{"key":"BFnrdp201744_CR89","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0140-6736(14)61186-7","volume":"384","author":"MK Leow","year":"2014","unstructured":"Leow, M. K. et al. Oncogenic osteomalacia presenting as a crippling illness in a young man. Lancet 384, 1236 (2014).","journal-title":"Lancet"},{"key":"BFnrdp201744_CR90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002560000306","volume":"30","author":"A Ogose","year":"2001","unstructured":"Ogose, A. et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 30, 99\u2013103 (2001).","journal-title":"Skeletal Radiol."},{"key":"BFnrdp201744_CR91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3892\/ol.2014.2081","volume":"8","author":"T Morimoto","year":"2014","unstructured":"Morimoto, T. et al. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol. Lett. 8, 67\u201371 (2014).","journal-title":"Oncol. Lett."},{"key":"BFnrdp201744_CR92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/adc.57.3.217","volume":"57","author":"K Kruse","year":"1982","unstructured":"Kruse, K., Kracht, U. & Gopfert, G. Renal threshold phosphate concentration (TmPO4\/GFR). Arch. Dis. Child. 57, 217\u2013223 (1982).","journal-title":"Arch. Dis. Child."},{"key":"BFnrdp201744_CR93","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","volume":"18","author":"S Liu","year":"2007","unstructured":"Liu, S. & Quarles, L. D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 18, 1637\u20131647 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrdp201744_CR94","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/ckj\/sfu070","volume":"7","author":"A Solano","year":"2014","unstructured":"Solano, A., Lew, S. Q. & Ing, T. S. Dent\u2013Wrong disease and other rare causes of the Fanconi syndrome. Clin. Kidney J. 7, 344\u2013347 (2014).","journal-title":"Clin. Kidney J."},{"key":"BFnrdp201744_CR95","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/ndt\/gfu377","volume":"30","author":"ED Klootwijk","year":"2015","unstructured":"Klootwijk, E. D. et al. Renal Fanconi syndrome: taking a proximal look at the nephron. Nephrol. Dial. Transplant. 30, 1456\u20131460 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrdp201744_CR96","first-page":"1871","volume":"7","author":"R Kumar","year":"2015","unstructured":"Kumar, R., Folpe, A. L. & Mullan, B. P. Tumor-induced osteomalacia. Transl Endocrinol. Metab. 7, 1871 (2015).","journal-title":"Transl Endocrinol. Metab."},{"key":"BFnrdp201744_CR97","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00198-016-3543-5","volume":"27","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche, D. et al. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos. Int. 27, 2345\u20132353 (2016).","journal-title":"Osteoporos. Int."},{"key":"BFnrdp201744_CR98","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz, R. et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23\u2013FGFR\u2013Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407\u2013412 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201744_CR99","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tem.2012.07.002","volume":"23","author":"N Bhattacharyya","year":"2012","unstructured":"Bhattacharyya, N., Chong, W. H., Gafni, R. I. & Collins, M. T. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol. Metab. 23, 610\u2013618 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnrdp201744_CR100","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel, E. A. et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 96, 3541\u20133549 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR101","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","volume":"44","author":"M Houang","year":"2013","unstructured":"Houang, M. et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum. Pathol. 44, 2711\u20132718 (2013).","journal-title":"Hum. Pathol."},{"key":"BFnrdp201744_CR102","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00223-010-9369-9","volume":"86","author":"A Ishii","year":"2010","unstructured":"Ishii, A. et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif. Tissue Int. 86, 455\u2013462 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"BFnrdp201744_CR103","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur, S. M. et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359, 761\u2013763 (2002).","journal-title":"Lancet"},{"key":"BFnrdp201744_CR104","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"Chong, W. H. et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J. Bone Miner. Res. 28, 1386\u20131398 (2013). An important paper that addresses the problem of tumour localization.","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/jc.2012-3642","volume":"98","author":"RJ Clifton-Bligh","year":"2013","unstructured":"Clifton-Bligh, R. J. et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET\/CT. J. Clin. Endocrinol. Metab. 98, 687\u2013694 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR106","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi, J. C. et al. Affinity profiles for human somatostatin receptor subtypes SST1\u2013SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273\u2013282 (2000).","journal-title":"Eur. J. Nucl. Med."},{"key":"BFnrdp201744_CR107","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche, D. et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 3575\u20133581 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR108","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1210\/jc.2013-3563","volume":"99","author":"MP Ferraz","year":"2014","unstructured":"Ferraz, M. P. et al. Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases. J. Clin. Endocrinol. Metab. 99, 699\u2013700 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2463\/mrms.2011-0006","volume":"12","author":"K Nakanishi","year":"2013","unstructured":"Nakanishi, K. et al. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia. Magn. Reson. Med. Sci. 12, 47\u201352 (2013).","journal-title":"Magn. Reson. Med. Sci."},{"key":"BFnrdp201744_CR110","doi-asserted-by":"publisher","unstructured":"Chakraborty, P. P., Bhattacharjee, R., Mukhopadhyay, S. & Chowdhury, S. \u2018Rachitic rosary sign\u2019 and \u2018tie sign\u2019 of the sternum in tumour-induced osteomalacia. BMJ Case Rep.http:\/\/dx.doi.org\/10.1136\/bcr-2016-214766 (2016).","DOI":"10.1136\/bcr-2016-214766"},{"key":"BFnrdp201744_CR111","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","volume":"26","author":"P Andreopoulou","year":"2011","unstructured":"Andreopoulou, P. et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J. Bone Miner. Res. 26, 1295\u20131302 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR112","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1210\/jc.2004-0406","volume":"89","author":"Y Takeuchi","year":"2004","unstructured":"Takeuchi, Y. et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89, 3979\u20133982 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR113","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-07-0779","volume":"158","author":"G van Boekel","year":"2008","unstructured":"van Boekel, G. et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur. J. Endocrinol. 158, 431\u2013437 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrdp201744_CR114","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3171\/2009.6.SPINE08120","volume":"11","author":"DM Sciubba","year":"2009","unstructured":"Sciubba, D. M. et al. En bloc spondylectomy for treatment of tumor-induced osteomalacia. J. Neurosurg. Spine 11, 600\u2013604 (2009).","journal-title":"J. Neurosurg. Spine"},{"key":"BFnrdp201744_CR115","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/ndt\/gfu217","volume":"29","author":"CA Wagner","year":"2014","unstructured":"Wagner, C. A., Rubio-Aliaga, I., Biber, J. & Hernando, N. Genetic diseases of renal phosphate handling. Nephrol. Dial. Transplant. 29 (Suppl. 4), iv45\u2013iv54 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrdp201744_CR116","first-page":"367","volume":"10","author":"JY Lee","year":"2013","unstructured":"Lee, J. Y. & Imel, E. A. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr. Endocrinol. Rev. 10 (Suppl. 2), 367\u2013379 (2013).","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"BFnrdp201744_CR117","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/rheumatology\/39.12.1415","volume":"39","author":"GP Clunie","year":"2000","unstructured":"Clunie, G. P., Fox, P. E. & Stamp, T. C. Four cases of acquired hypophosphataemic (\u2018oncogenic\u2019) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxford) 39, 1415\u20131421 (2000).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrdp201744_CR118","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.anl.2008.01.003","volume":"36","author":"N Uramoto","year":"2009","unstructured":"Uramoto, N., Furukawa, M. & Yoshizaki, T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 36, 104\u2013105 (2009).","journal-title":"Auris Nasus Larynx"},{"key":"BFnrdp201744_CR119","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","volume":"35","author":"WJ Yu","year":"2017","unstructured":"Yu, W. J., He, J. W., Fu, W. Z., Wang, C. & Zhang, Z. L. Reports of 17 Chinese patients with tumor-induced osteomalacia. J. Bone Miner. Metab. 35, 298\u2013307 (2017).","journal-title":"J. Bone Miner. Metab."},{"key":"BFnrdp201744_CR120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2265.1992.tb02342.x","volume":"37","author":"JN Harvey","year":"1992","unstructured":"Harvey, J. N., Gray, C. & Belchetz, P. E. Oncogenous osteomalacia and malignancy. Clin. Endocrinol. (Oxf.) 37, 379\u2013382 (1992).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrdp201744_CR121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","volume":"16","author":"ZJ Sun","year":"2015","unstructured":"Sun, Z. J., Jin, J., Qiu, G. X., Gao, P. & Liu, Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet. Disord. 16, 43 (2015).","journal-title":"BMC Musculoskelet. Disord."},{"key":"BFnrdp201744_CR122","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12957-015-0763-7","volume":"14","author":"J Dadoniene","year":"2016","unstructured":"Dadoniene, J. et al. Tumour-induced osteomalacia: a literature review and a case report. World J. Surg. Oncol. 14, 4 (2016).","journal-title":"World J. Surg. Oncol."},{"key":"BFnrdp201744_CR123","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","volume":"17","author":"AH Hautmann","year":"2015","unstructured":"Hautmann, A. H., Hautmann, M. G., Kolbl, O., Herr, W. & Fleck, M. Tumor-induced osteomalacia: an up-to-date review. Curr. Rheumatol. Rep. 17, 512 (2015).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrdp201744_CR124","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2009.07.1704","volume":"78","author":"W Ruka","year":"2010","unstructured":"Ruka, W. et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int. J. Radiat. Oncol. Biol. Phys. 78, 494\u2013498 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrdp201744_CR125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0360-3016(03)00416-4","volume":"57","author":"JJ Caudell","year":"2003","unstructured":"Caudell, J. J. et al. Radiotherapy in the management of giant cell tumor of bone. Int. J. Radiat. Oncol. Biol. Phys. 57, 158\u2013165 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrdp201744_CR126","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1210\/jc.2012-1719","volume":"97","author":"S Tutton","year":"2012","unstructured":"Tutton, S., Olson, E., King, D. & Shaker, J. L. Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation. J. Clin. Endocrinol. Metab. 97, 3421\u20133425 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR127","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc070347","volume":"357","author":"E Hesse","year":"2007","unstructured":"Hesse, E., Rosenthal, H. & Bastian, L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N. Engl. J. Med. 357, 422\u2013424 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201744_CR128","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJM200205303462215","volume":"346","author":"F Paglia","year":"2002","unstructured":"Paglia, F., Dionisi, S. & Minisola, S. Octreotide for tumor-induced osteomalacia. N. Engl. J. Med. 346, 1748\u20131749 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201744_CR129","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","volume":"345","author":"J Seufert","year":"2001","unstructured":"Seufert, J. et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med. 345, 1883\u20131888 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201744_CR130","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","volume":"92","author":"A Khosravi","year":"2007","unstructured":"Khosravi, A. et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 92, 2374\u20132377 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR131","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4158\/EP.11.2.108","volume":"11","author":"MB Zimering","year":"2005","unstructured":"Zimering, M. B., Caldarella, F. A., White, K. E. & Econs, M. J. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr. Pract. 11, 108\u2013114 (2005).","journal-title":"Endocr. Pract."},{"key":"BFnrdp201744_CR132","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jocd.2005.11.001","volume":"9","author":"R Bhambri","year":"2006","unstructured":"Bhambri, R. et al. Changes in bone mineral density following treatment of osteomalacia. J. Clin. Densitom. 9, 120\u2013127 (2006).","journal-title":"J. Clin. Densitom."},{"key":"BFnrdp201744_CR133","unstructured":"Collins, M. T. et al. Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. Annual Meeting of the American Society for Bone and Mineral Research SA0035 (2015)."},{"key":"BFnrdp201744_CR134","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/en.2011-1831","volume":"153","author":"MY Zhang","year":"2012","unstructured":"Zhang, M. Y. et al. Chronic inhibition of ERK1\/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153, 1806\u20131816 (2012).","journal-title":"Endocrinology"},{"key":"BFnrdp201744_CR135","unstructured":"Carpenter, T. O. et al. Effects of KRN23, an anti-FGF23 antibody, in patients with tumor induced osteomalacia and epidermal nevus syndrome: results from an ongoing phase 2 study. Annual Meeting of the American Society for Bone and Mineral Research 1098 (2016)."},{"key":"BFnrdp201744_CR136","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono, Y. et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J. Bone Miner. Res. 24, 1879\u20131888 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR137","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 124, 1587\u20131597 (2014). A study that shows the effect of pharmacological treatment in patients with X-linked hypophosphataemia.","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201744_CR138","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel, E. A. et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J. Clin. Endocrinol. Metab. 100, 2565\u20132573 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrdp201744_CR139","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J. Clin. Pharmacol. 56, 176\u2013185 (2016).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrdp201744_CR140","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00223-015-0029-y","volume":"98","author":"S Fukumoto","year":"2016","unstructured":"Fukumoto, S. FGF23\u2013FGF receptor\/klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif. Tissue Int. 98, 334\u2013340 (2016). An extensive review that discusses the potential of the FGF23\u2013FGFR\u2013KLOTHO complex as a therapeutic target.","journal-title":"Calcif. Tissue Int."},{"key":"BFnrdp201744_CR141","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf, M. & White, K. E. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 23, 411\u2013419 (2014).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrdp201744_CR142","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf, M., Koch, T. A. & Bregman, D. B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28, 1793\u20131803 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrdp201744_CR143","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2042018816678363","volume":"8","author":"RH Bishay","year":"2017","unstructured":"Bishay, R. H., Ganda, K. & Seibel, M. J. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther. Adv. Endocrinol. Metab. 8, 14\u201319 (2017).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"BFnrdp201744_CR144","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mam.2012.12.009","volume":"34","author":"MA Hediger","year":"2013","unstructured":"Hediger, M. A., Clemencon, B., Burrier, R. E. & Bruford, E. A. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Aspects Med. 34, 95\u2013107 (2013).","journal-title":"Mol. Aspects Med."},{"key":"BFnrdp201744_CR145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.mam.2012.05.004","volume":"34","author":"RJ Reimer","year":"2013","unstructured":"Reimer, R. J. SLC17: a functionally diverse family of organic anion transporters. Mol. Aspects Med. 34, 350\u2013359 (2013).","journal-title":"Mol. Aspects Med."},{"key":"BFnrdp201744_CR146","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mam.2012.07.007","volume":"34","author":"IC Forster","year":"2013","unstructured":"Forster, I. C., Hernando, N., Biber, J. & Murer, H. Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med. 34, 386\u2013395 (2013).","journal-title":"Mol. Aspects Med."},{"key":"BFnrdp201744_CR147","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-030212-183748","volume":"75","author":"J Biber","year":"2013","unstructured":"Biber, J., Hernando, N. & Forster, I. Phosphate transporters and their function. Annu. Rev. Physiol. 75, 535\u2013550 (2013).","journal-title":"Annu. Rev. Physiol."},{"key":"BFnrdp201744_CR148","doi-asserted-by":"crossref","first-page":"e0125104","DOI":"10.1371\/journal.pone.0125104","volume":"10","author":"G Albano","year":"2015","unstructured":"Albano, G. et al. Sodium-dependent phosphate transporters in osteoclast differentiation and function. PLoS ONE 10, e0125104 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrdp201744_CR149","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/joe.0.1810531","volume":"181","author":"E Zoidis","year":"2004","unstructured":"Zoidis, E., Ghirlanda-Keller, C., Gosteli-Peter, M., Zapf, J. & Schmid, C. Regulation of phosphate (Pi) transport and NaPi-III transporter (Pit-1) mRNA in rat osteoblasts. J. Endocrinol. 181, 531\u2013540 (2004).","journal-title":"J. Endocrinol."},{"key":"BFnrdp201744_CR150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbrc.2012.04.077","volume":"422","author":"CM Cowan","year":"2012","unstructured":"Cowan, C. M. et al. NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2. Biochem. Biophys. Res. Commun. 422, 351\u2013357 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrdp201744_CR151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1116\/1.2354575","volume":"1","author":"L Wang","year":"2006","unstructured":"Wang, L., Nancollas, G. H., Henneman, Z. J., Klein, E. & Weiner, S. Nanosized particles in bone and dissolution insensitivity of bone mineral. Biointerphases 1, 106\u2013111 (2006).","journal-title":"Biointerphases"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrdp201744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201744","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrdp201744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:20:05Z","timestamp":1671747605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrdp201744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,21]]}},"alternative-id":["BFnrdp201744"],"URL":"https:\/\/doi.org\/10.1038\/nrdp.2017.44","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]},"assertion":[{"value":"13 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. has served as speaker for Abiogen, Amgen, Diasorin, Eli Lilly, Italfarmaco, Fujii, Merck Sharp & Dohme and Takeda. He has also served on the advisory boards of Amgen and Eli Lilly. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17044"}}